Floatz logo

Humax-Cd20

B Lymphoblastic Lymphoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the B Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
National Cancer Institute (NCI)
Phase 3BB
Inno-206
Alliance for Clinical Trials in Oncology
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
Cytosin-Arabinosid
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 22 →

Same molecule, other indications

Humax-Cd20 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →